Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-75.36%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-75.36%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
0.9
-14x
Never
—
-100.00%
40%
—
5 Years
Score0.9
Net Growth-14x
Net TrendNever
Net Income Consistency—
Rev Growth-100.00%
Rev Trend40%
Revenue Consistency—
Inhibikase Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 698.47K to $ 0.00 and net income went from -$ 2M to -$ 48M. Revenue increased in 2 of those 5 years; net income in 0.
Inhibikase Therapeutics Inc currently holds a 5-year HDB Score of 0.9 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.40 | — |
1 Year2025-08-12 | $ 1.75 | 37.14% |
5 Years2021-08-12 | $ 12.12 | -80.20% |
All Time2020-12-23 | $ 59.40 | -95.96% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-12-23 |
|---|---|---|---|---|
| Price | $ 2.40 | $ 1.75 | $ 12.12 | $ 59.40 |
| Return | — | 37.14% | -80.20% | -95.96% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2025 | $ 0.00 | -$ 48M | $ 178M |
| 2024 | $ 0.00 | -$ 27M | $ 97M |
| 2023 | $ 260.5K | -$ 19M | $ 13M |
| 2022 | $ 123.44K | -$ 18M | $ 23M |
| 2021 | $ 3M | -$ 14M | $ 40M |
| IPO2020 | $ 698.47K | -$ 2M | $ 13M |
Explore beyond IKT
You're looking at Inhibikase Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
